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Hepatitis C virus (HCV) entry is dependent on CD81. To investigate whether the CD81 sequence is a
determinant of HCV host range, we expressed a panel of diverse CD81 proteins and tested their ability to
interact with HCV. CD81 large extracellular loop (LEL) sequences were expressed as recombinant proteins;
the human and, to a low level, the African green monkey sequences bound soluble HCV E2 (sE2) and inhibited
infection by retrovirus pseudotype particles bearing HCV glycoproteins (HCVpp). In contrast, mouse or rat
CD81 proteins failed to bind sE2 or to inhibit HCVpp infection. However, CD81 proteins from all species, when
expressed in HepG2 cells, conferred susceptibility to infection by HCVpp and cell culture-grown HCV to
various levels, with the rat sequence being the least efficient. Recombinant human CD81 LEL inhibited HCVpp
infectivity only if present during the virus-cell incubation, consistent with a role for CD81 after virus attach-
ment. Amino acid changes that abrogate sE2 binding (I182F, N184Y, and F186S, alone or in combination) were
introduced into human CD81. All three amino acid changes in human CD81 resulted in a molecule that still
supported HCVpp infection, albeit with reduced efficiency. In summary, there is a remarkable plasticity in the
range of CD81 sequences that can support HCV entry, suggesting that CD81 polymorphism may contribute to,
but alone does not define, the HCV susceptibility of a species. In addition, the capacity to support viral entry
is only partially reflected by assays measuring sE2 interaction with recombinant or full-length CD81 proteins.
Hepatitis C virus (HCV) is an enveloped, positive-strand
RNA virus and is the sole member of the Hepacivirus genus of
the family Flaviviridae. An estimated 170 million individuals
worldwide are infected with HCV and are at risk for the de-
velopment of chronic liver disease and hepatocellular carci-
noma. Animal models that support HCV infection are limited
to the chimpanzee, an endangered species available in limited
numbers, and immunodeficient mice with transplanted human
hepatocytes.
HCV encodes two envelope glycoproteins, E1 and E2, which
confer liver cell specificity to retroviral pseudotype particles
(HCVpp) (3, 9, 18). The availability of HCVpp enabled func-
tional studies of the glycoproteins (4, 10, 12, 18, 33), measure-
ment of HCV-specific neutralizing antibodies (2, 26, 31, 47),
and elucidation of cellular receptors required for viral entry (3,
4, 7, 29, 49). The recent discovery that the JFH strain of HCV
is able to replicate and release infectious virus particles in cell
culture (HCVcc) allows comparative studies on the entry pro-
cesses of HCVcc and HCVpp (25, 46, 50).
Soluble, truncated forms of E2 (sE2) bind to human cells
and were used to identify interactions with several cell surface
molecules, including CD81 (35), scavenger receptor class B
type I (SR-BI) (40), and dendritic cell-specific intercellular
adhesion molecule 3-grabbing nonintegrin (DC-SIGN) (14,
27, 37).
CD81 is a member of the tetraspanin superfamily, possess-
ing short intracellular N and C termini, four transmembrane
domains, a small extracellular loop (SEL), and a large extra-
cellular loop (LEL) (23, 24). The critical role of CD81 in HCV
entry was demonstrated by experiments showing that HCVpp
infection of primary human hepatocytes or hepatoma cell lines
was inhibited by CD81-specific monoclonal antibodies (MAbs)
or recombinant CD81 protein (3, 18), that infection of the
Huh-7 hepatoma cell line was inhibited when CD81 expression
was silenced by specific small interfering RNAs, and that
CD81-negative HepG2 cells supported HCVpp infection when
transduced to express CD81 (4, 49). Similar approaches con-
firmed that HCVcc infection is also dependent on CD81 ex-
pression (25, 46, 50). The LEL of CD81 was shown to bind sE2
(13, 35), and characterization of chimeric CD9/CD81 mole-
cules confirmed that the LEL sequence is a determinant of
HCVpp entry (49). We previously reported that sE2 binds to
human but not to mouse, rat, or African green monkey (AGM)
CD81 proteins, suggesting that CD81 may be a determinant of
the species restriction of HCV infection (13, 15). However,
CD81 cannot be the sole determinant, as transgenic mice ex-
pressing human CD81 fail to support HCV infection (28). In
addition, tamarin CD81 has been reported to bind sE2, but
tamarins are not susceptible to infection by HCV (1, 30).
SR-BI is a member of the scavenger receptor family and
binds sE2 (40). Silencing of SR-BI expression and treatment of
target cells with anti-SR-BI antibodies inhibited HCVpp infec-
tion, suggesting a role for SR-BI during HCV infection (4, 22).
However, multiple cell lines expressing both SR-BI and CD81
fail to support HCVpp infection, indicating that additional
factors are required for HCV entry (4, 18).
The recently reported HCVpp and HCVcc systems permit
studies of the complete HCV entry mechanism, as opposed to
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the binding assays with recombinant proteins that were previ-
ously possible. Thus, the objectives of our study were to use
HCVpp and HCVcc to (i) determine to what extent CD81
defines species restriction of HCV infection; (ii) assess whether
assays using recombinant, truncated sE2 or CD81 LEL proteins
predict the capacity of a CD81 sequence to support viral in-
fection; and (iii) identify residues within CD81 that are critical
for its receptor function. We expressed and characterized a
panel of CD81 proteins, both as recombinant LEL fusion pro-
teins and as full-length molecules in HepG2 cells, for their
interaction with HCV. Our data show that CD81 derived from
a broad range of species can support HCVpp and HCVcc
infection and suggest that recombinant proteins are poor mim-
ics for interactions between cellular CD81 and HCV. These
findings have implications for the development of small animal
models supporting HCV infection and for the design of inhib-
itors targeting CD81-dependent HCV entry.
MATERIALS AND METHODS
Cells and antibodies. 293T, Hep3B, BHK, and CV-1 cells were from the
American Type Culture Collection (ATCC) and were propagated according to
ATCC recommendations. HepG2 cells (a gift of Yoshiharu Matsuura, Osaka
University, Osaka, Japan) were propagated in Dulbecco’s modified Eagle me-
dium (DMEM) supplemented with 10% fetal bovine serum (FBS). HepG2 cells
were propagated on collagen type 1-coated tissue culture vessels. The mouse
liver cell line Hepa1-6 was also obtained from the ATCC and propagated ac-
cording to ATCC recommendations. All cells were grown at 37°C in 5% CO2.
Rat anti-E2 MAbs 6/1a, 7/59, and 7/16 have been described previously (13).
Anti-glutathione S-transferase (GST) antibody was purchased from Sigma (St.
Louis, MO) and anti-His6 antibody from Invitrogen (Carlsbad, CA). The MAbs
1.3.3.22 (Santa Cruz Biotechnology, Santa Cruz, CA), 1D6 (Serotec, Raleigh,
NC) and JS-81 (BD Biosciences, San Jose, CA) against human CD81, and
EAT-2 (Santa Cruz Biotechnology) against mouse CD81 were employed in this
study. Horseradish peroxidase (HRP)-conjugated anti-mouse antibody was from
Pierce (Rockford, IL). Anti-rat and anti-Armenian hamster antibodies were
from Jackson ImmunoResearch (West Grove, PA). Alexa 488-conjugated anti-
bodies were from Molecular Probes (Eugene, OR).
Cloning of CD81 cDNAs from different species. The cDNAs for CD81 from
several species were amplified by reverse transcription (RT)-PCR as described
previously for the human CD81 sequence (49). RNA from tamarin and chim-
panzee peripheral blood mononuclear cells was kindly provided by Robert
Lanford (Southwest National Primate Research Center, San Antonio, TX). Rat,
hamster, mouse, and AGM RNAs were isolated from the Rat-2, BHK, Hepa1-6,
and CV-1 cell lines, respectively. RNA was extracted from between 3  106 and
7  106 of the appropriate cells by using the RNeasy minikit (QIAGEN, Valen-
cia, CA), and RT was performed using SuperScript II (Invitrogen) according to
the manufacturer’s instructions with RU-O-4109 (5-GCG CTC GAG TCA
GTA CAC GGA GCT GTT CC-3; the CD81 stop codon is underlined). PCR
products were amplified with oligonucleotide primers RU-O-4104 (5-CGC
GGA TCC GCC ACC ATG GGA GTG GAG GGC TGC ACC-3; the CD81
start codon is underlined) and RU-O-4109 and the Advantage 2 PCR kit (Clon-
tech, Palo Alto, CA). The resulting PCR products were digested with BamHI
and XhoI and were ligated with the similarly digested human immunodeficiency
virus (HIV) vector pTRIP-EGFP (48). For expression of GST-CD81 LEL fusion
proteins in Escherichia coli, cDNAs encoding residues 112 to 202 of human,
AGM, rat, and mouse CD81 were amplified by PCR, using the appropriate
pTRIP clones as templates. A C-terminal His6 tag was introduced during PCR
through inclusion in the antisense primer. The resulting PCR products were
ligated with pGEX-6P (Novagen, Madison, WI) by standard techniques.
Cloning of human-rat and rat-human chimeric CD81 proteins. Small and
large extracellular loop exchanges were made by amplifying the SEL or LEL
fragments from 25 ng of the human or rat CD81 expression plasmids, using a
proofreading polymerase (Roche Expand). Human or rat SEL was amplified
using the primers RU-O-4104 and CD81SEL/LELPst1 (CCA GAT GCC TGC
AGC TAC CTC ACA GGC; the silent PstI site is underlined), and the human
or rat LEL was amplified using the primers CD81SEL/LELPst1 (GCC TGT
GAG GTA GCT GCA GGC ATC TGG; the silent PstI site is underlined) and
RU-O-4109. PCR products were gel purified (QIAGEN Minelute kit), digested
with BamHI and PstI (SEL) or PstI and XhoI (LEL), and ligated with gel-
purified BamHI/XhoI-digested pTRIP-EGFP. Clones containing the correct
fragments were verified by sequencing.
Expression and purification of GST-CD81 LEL fusion proteins. A single
colony of Rosetta-gami Escherichia coli (Novagen), freshly transformed with the
appropriate GST-CD81 LEL expression plasmid, or the empty vector was used
to seed a starter culture of Luria broth (LB) supplemented with 15 g/ml
kanamycin, 12.5 g/ml tetracycline, 34 g/ml chloramphenicol, and 100 g/ml
ampicillin This culture was incubated in an orbital shaker at 250 rpm overnight
at 37°C and then diluted 1 to 100 into fresh LB (supplemented with antibiotics
as previously) and incubated at 30°C and 250 rpm until an optical density at 600
nm of 0.6 to 0.8 was reached. Expression was induced by the addition of iso-
propyl-1-thio--D-galactopyranoside to a final concentration of 100 M and the
culture incubated overnight at 18°C and 250 rpm. Cells were collected by cen-
trifugation at 6,000  g for 15 min at 4°C.
For purification of GST-CD81 LEL fusion proteins, the cell pellets were
resuspended in lysis buffer (1 phosphate-buffered saline [PBS], 10% glycerol)
and lysed by three passages through an Avestin air emulsifier at 15,000 lb/in2.
Lysates were clarified at 25,000  g for 30 min at 4°C, and the clarified extracts
were applied to GSTrap FF affinity columns according to the manufacturer’s
instructions (Amersham Biosciences, Piscataway, NJ). Columns were washed
with 5 column volumes of lysis buffer, and GST fusion proteins were eluted with
5 column volumes of elution buffer (100 mM Tris-HCl, pH 8.0; 150 mM KCl; 15
mM reduced glutathione). Fractions of the eluate were collected and analyzed
for protein content by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Coomassie blue staining. Peak fractions were pooled, ali-
quoted, and stored at 80°C. Concentrations of partially purified GST-CD81
LEL fusion proteins were determined using the Bio-Rad protein assay (Bio-Rad,
Hercules, CA).
EIA for E2 binding to GST-CD81 LEL. The enzyme-linked immunoassay
(EIA) was described previously (15). Briefly, GST-CD81 LEL fusion proteins
were used to coat 96-well plates at 5 g/ml in PBS overnight at 4°C. Plates were
blocked for 1 h at room temperature with PBS supplemented with 5% bovine
serum albumin. Supernatant from a culture of 293T cells transfected to express
the sE2 protein was used as a source of E2 protein truncated at residue 661, as
previously described (13). Serial dilutions of sE2 were allowed to bind at 4°C
overnight in antibody diluent (1 PBS, 5% bovine serum albumin, 20% sheep
serum, 0.05% Tween 20). After washing, bound sE2 was detected using rat
anti-E2 antibodies 6/1a, 7/59, and 7/16, each diluted 1:10 in antibody diluent, for
1 h at room temperature, followed by HRP-conjugated anti-rat immunoglobulin
and tetramethylbenzidine substrate. Absorbance was measured at 450 nm.
Generation of retroviral pseudotype particles and infection assay. HIV
pseudotype viruses were generated as previously described (18). Briefly, 293T cells
were cotransfected with an HCV E1E2 expression plasmid and pNL4.3.Luc.RE,
using Lipofectamine 2000 (Invitrogen). Lipid-DNA complexes were removed 4 to
6 h later and replaced with DMEM supplemented with 3% FBS. At 48 h, or 72 h for
HCVpp-J6, posttransfection the culture medium was collected, clarified by low-
speed centrifugation for 20 min, and then aliquoted and stored at80°C before use.
The particulate p24 content of pseudotype virus preparations was assessed as
described previously (12). HCVpp were pelleted through a sucrose cushion,
resuspended in PBS supplemented with 1% Empigen, and heat inactivated. The
p24 content was quantified by EIA.
HCVpp infectivity was measured as previously described (18). Target cells were
seeded at 8  103 cells per well of a 96-well plate the day prior to infection. For
infection, medium was removed and pseudotype virus, diluted in DMEM supple-
mented with 3% FBS, was added. After overnight incubation, the inoculum was
removed and replaced with DMEM supplemented with 3% FBS. At 72 h postin-
fection, the medium was removed and the cells lysed with 40 l of cell lysis buffer
(Promega, Madison, WI) per well. Luciferase activity was assayed by the addition of
35 l of lysate to 50 l of luciferase substrate and measured for 5 s in a luminometer
(Lumat LB 9507). To study inhibition by soluble CD81 LEL, HCVpp was incubated
with GST-CD81 LEL fusion protein for 1 h at 37°C prior to addition to the target
cells. Alternatively, GST-CD81 LEL was incubated with Huh-7.5 target cells for 1 h
at 37°C, and the cells were washed prior to addition of HCVpp.
Transduction of cells to express CD81. HepG2 cells were transduced to ex-
press CD81 or CD9 as previously described (49). Briefly, packaged lentiviruses to
express CD81 were generated by cotransfection of 293T cells with a plasmid
encoding vesicular stomatitis virus G protein, a plasmid encoding HIV Gag-Pol,
and pTRIP-CD81 (1:3:3 ratio). HepG2 cells were seeded at 8 105 cells per well
of a six-well plate and infected 24 h later with the packaged lentivirus in DMEM
supplemented with 3% FBS and 4 g/ml Polybrene. After 12 h, cells were
washed, trypsinized, and seeded into appropriate plates either for pseudotype
virus infection or for flow cytometry.
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Flow cytometry. Cell surface CD81 expression was monitored by live cell
staining with CD81-specific antibodies and irrelevant species- and isotype-
matched antibodies. To detect human, AGM, chimpanzee, and tamarin CD81
sequences, MAbs 1.3.3.22 and JS-81 were used, while MAb EAT-2 was used to
detect the mouse and rat CD81 proteins. Binding of sE2 to cells was assayed as
previously described (13). Analyses were performed using a FACScalibur flow
cytometer (BD Biosciences) and FlowJo software (Tree Star, San Carlos, CA).
HCVcc generation and infection assays. Infectious J6/JFH particles were gen-
erated as previously described (25). Briefly, RNA was transcribed in vitro from a
chimeric full-length J6/JFH genome by using the Megascript T7 kit (Ambion, Aus-
tin, TX) and electroporated into Huh-7.5 cells. Alternatively, a J6/JFH genome with
a Renilla luciferase reporter upstream of core (fl-J6/JFH-5C19Rluc2AUbi) was
used (referred to here as J6/JFH(Rluc2Aubi); this construct is described else-
where [45]). At 48 h, 96 h, and 8 days after electroporation, supernatants were
collected, filtered, pooled, and stored at 4°C. One day before infection, target
cells were seeded at 5  104 cells per well in 6-well plates for infection with
J6/JFH or in 12-well plates for infection with J6/JFH(Rluc2AUbi). For infection,
the pooled HCVcc-containing supernatant with HEPES (20 mM) and Polybrene
(4 g/ml) was applied undiluted. at 24 h after infection, the supernatants were
replaced with regular growth medium. At 72 h postinoculation, infection was
detected by methanol fixation and staining for NS5A antigen, using the anti-
NS5A MAb 9E10 as a primary antibody and HRP-conjugated anti-mouse im-
munoglobulin G (Vector Laboratories, Burlingame, CA) as a secondary anti-
body. Alternatively, infection with J6/JFH(Rluc.2A.Ubi) was detected 48 or 72 h
postinfection by measuring luciferase activity after lysis with 250 l of Renilla
luciferase lysis buffer (Promega) and addition of 100 l Renilla luciferase sub-
strate (Promega) to 100 l of lysate.
RESULTS
Interaction of recombinant CD81 proteins with sE2 and
HCVpp. To assess CD81 sequence polymorphism, RNA was
extracted from human, chimpanzee, tamarin, AGM, mouse,
FIG. 1. Alignment of the inferred CD81 amino acid sequences used in this study. Amino acids that differ from the human sequence are shown.
Residues predicted to be included in the four transmembrane domains are indicated by dark shading: TMD1 residues 11 to 36, TMD2 residues
59 to 64, TMD3 residues 89 to 114, and TMD4 residues 203 to 228 (41). The LEL (residues 115 to 202) is indicated by light shading. Letters
indicating the secondary structure of the LEL are above the sequences (20) (H, -helix; G, 310 helix). Cysteine residues connected by disulfide
bonds are indicated by numbers below the sequence (1, Cys156-Cys190; 2, Cys157-Cys175). Asterisks below the sequence indicate amino acid
positions that, in the context of the complete human CD81 molecule, have previously been shown to be important for the interaction with a
truncated E2: I182, N184, F186, and D196. Note that the human and chimpanzee amino acid sequences are identical.
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rat, and hamster cells and CD81 cDNA amplified by RT-PCR.
The open reading frames were cloned into the pTRIP lentiviral
vector, and the clones were sequenced and aligned (Fig. 1).
Among the seven species tested, 26 residues (11% of 236) were
polymorphic, and the majority of these residues were located
within the LEL (21/89; 24%).
To examine the effect of CD81 polymorphism on sE2 pro-
tein binding, several species were selected and expressed as
recombinant LEL fusion proteins. The observation that con-
served LEL cysteine residues are important for the interaction
with sE2 (15, 20, 34) led us to optimize our protocol for
expressing CD81 fusion proteins. To enhance native protein
folding and conformation, CD81 amino acid residues 112 to
202 were expressed as GST- and His6-tagged proteins in an E.
coli strain that favors disulfide bond formation. To assess di-
sulfide bond formation, the proteins were analyzed by reducing
and nonreducing SDS-PAGE and detection by anti-CD81
MAbs whose reactivity is dependent upon disulfide bond in-
tegrity (Fig. 2A). The proteins were also characterized for their
ability to bind antibodies whose recognition is independent of
oxidation state (anti-GST, anti-His6, and anti-human CD81
MAb 1D6). After separation under reducing conditions, both
anti-GST and anti-His6 antibodies recognized proteins of the
expected molecular weights. However, under nonreducing con-
FIG. 2. Characterization of GST-CD81 LEL fusion proteins and inhibition of HCVpp infectivity. (A) Formation of disulfide bonds in GST-CD81
LEL fusion proteins. Fusion proteins with the human, AGM, mouse, or rat LEL sequence, or GST alone, were isolated on glutathione-Sepharose and
separated by reducing or nonreducing SDS-PAGE (12% polyacrylamide gels). Immunoblotting was performed with anti-GST, anti-His6, or anti-CD81
(1.3.3.22, 1D6, or EAT-2) antibodies. The migration of molecular mass markers is indicated (in kilodaltons). The expected molecular mass of the
reduced GST-CD81 LEL proteins was 33 kDa. (B) Binding of truncated strain H sE2 protein to GST-CD81 LEL fusion proteins. A serial
dilution of sE2 protein was allowed to bind to EIA plates coated with GST-CD81 LEL proteins. After washing, bound sE2 was detected using
anti-E2 specific MAbs and anti-rat–HRP. Each dilution was tested in triplicate, and the mean absorbance is shown with standard deviation bars
(not visible for many points). Absorbance readings obtained with GST, GST-mouse CD81 LEL, and GST-rat CD81 LEL were similar (coefficient
of variation, 	11%) hence only GST is shown for clarity. O.D., optical density. (C) Inhibition of HCVpp infection by GST-CD81 LEL fusion
proteins. Pseudoparticles were generated and the particulate p24 content of the preparations was determined as described in Materials and
Methods. Prior to infection of Hep3B cells, 1 ng of particulate p24 of each pseudoparticle preparation (no env, E1E2, or MLV) was incubated at
37°C for 1 h with GST-CD81 LEL fusion proteins. Three days after infection, cells were lysed and luciferase activity determined. All infections
were performed in quadruplicate, and the mean luciferase activity is shown. Depicted are results from a representative of three separate
experiments. RLU, relative light units.
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ditions, these antibodies detected a diffusely migrating species
containing at least two distinct bands. The differences in mi-
gration were most likely due to the formation of disulfide
bonds within GST, as a similar pattern was observed when
GST alone was expressed. As anticipated, MAb 1D6 recog-
nized GST-human CD81 LEL under both reducing and non-
reducing conditions, whereas MAb 1.3.3.22 detected GST-
human CD81 LEL only after nonreducing SDS-PAGE. The
EAT-2 MAb recognized both mouse and rat LEL proteins,
and recognition was decreased following reduction (detection
of the GST-rat CD81 LEL protein under reducing conditions
was more apparent after longer exposures). These data suggest
that correct disulfide bonds were formed in the GST-human,
mouse, and rat CD81 LEL fusion proteins, allowing the for-
mation of the 1.3.3.22 and EAT-2 epitopes. Due to the lack of
an antibody reactive against the SDS-denatured protein, we
were unable to confirm disulfide bond formation in the GST-
AGM CD81 LEL fusion protein.
The CD81 fusion proteins were tested for their ability to
bind strain H sE2 by EIA. sE2 bound readily to the human
sequence and failed to interact with GST alone or the mouse
and rat LEL sequences (Fig. 2B and data not shown). The
GST-AGM CD81 LEL bound low levels of sE2, contrary to
our previous report (15), which may reflect our modified
protocol for expression of fusion proteins with native LEL
conformation. To study GST-CD81 LEL interaction with
functional E1E2 glycoproteins, the GST fusion proteins
were tested for their ability to neutralize HCVpp infectivity.
Infection with pseudotypes bearing no viral glycoproteins
(no Env; negative control) or the murine leukemia virus
(MLV) glycoprotein (MLVpp; positive control) was unaf-
fected by the proteins. GST-human CD81 LEL inhibited
HCVpp infectivity, while addition of GST alone or the GST-
mouse or rat LEL proteins had no effect (Fig. 2C). Consis-
tent with the EIA data, GST-AGM CD81 LEL partially
inhibited HCVpp infectivity (Fig. 2C).
Recombinant forms of tetraspanin LELs have been reported to
affect cellular functions such as sperm-egg fertilization, leukocyte
adhesion and monocyte fusion (16, 44). More recently, a range of
recombinant tetraspanin LELs was reported to inhibit HIV in-
fection of macrophages by interacting with the target cell and
associating with endogenous tetraspanins (17). To assess whether
human CD81 LEL inhibits HCVpp infectivity by interacting with
the target cell, recombinant human and mouse CD81 LEL pro-
teins were incubated with Huh-7.5 cells for 1 hour at 37°C, any
unbound protein removed by washing, and the cells challenged
with HCVpp and MLVpp. Alternatively, LEL proteins were in-
cubated with HCVpp and MLVpp for 1 hour prior to infection.
Human CD81 LEL inhibited HCVpp infectivity when incubated
with the virus and not with the target cells, suggesting a mecha-
nism of action dependent upon an interaction with the virus
particle (Fig. 3A). Next we incubated a high-titer preparation of
FIG. 3. GST-CD81 inhibition of HCVpp infectivity. (A) Human and mouse GST-CD81 LEL (hLEL and mLEL, respectively) proteins were
either added to Huh-7.5 cells (“cells”) and incubated for 1 h at 37°C before cells were washed and pseudoparticles added, or CD81 LEL was mixed
with pseudoparticles (“virus”) for 1 h at 37°C before adding the mixture to cells. In both cases the final concentration of CD81 LEL was 10 g/ml.
White bars represent HCVpp-H77; shaded bars represent MLVpp. Three days after infection, cells were lysed and luciferase activity determined.
Cells infected with no-Env control virus gave a mean luciferase reading of 2,134 
 308 (data not shown). (B and C) A high-titer infectious
preparation of HCVpp-H77 was incubated with no inhibitor or with 5 g/ml of human CD81 LEL and C1 anti-E2 MAb for 1 h at 37°C before
infection. (B) Aliquots of the untreated and treated virus mixtures were tested for infectivity on Huh-7.5 cells. (C) The remaining virus was diluted
60-fold (to reduce the CD81 LEL and C1 to a biologically inactive concentration) and tested for infectivity in the presence and absence of
additional human CD81 LEL and C1 MAb at a final concentration of 5 g/ml. Three days after infection, cells were lysed and luciferase activity
determined. Cells infected with no-Env control virus gave mean luciferase readings of 5,006 
 715 and 856 
 92 at the two respective dilutions
(data not shown). (D and E) Human and AGM CD81 LEL inhibition of HCVpp-H77 infection of HepG2 cells expressing either human (D) or
AGM (E) CD81. All infections were performed in triplicate, and the data are representative of two independent experiments (mean 
 standard
deviation). RLU, relative light units.
VOL. 80, 2006 CD81 SEQUENCE REQUIREMENTS FOR HCV ENTRY 11335
 at UNIV O
F BIRM
ING
HAM
 on M
ay 9, 2007 
jvi.asm.org
D
ow
nloaded from
 
HCVpp with either CD81 LEL or a neutralizing anti-E2 MAb
(C1) at 5 g/ml for 1 hour at 37°C. As expected, a strong
inhibition was observed with both treatments (Fig. 3B). To test
the hypothesis that CD81 LEL and C1 inactivate virus particles
through binding to them, we performed the same preincu-
bation (no inhibitor, CD81 LEL, or C1 anti-E2) and then
diluted the mixture 60-fold to reduce the CD81 LEL and C1
to an ineffective concentration of 0.08 g/ml (Fig. 2C and
data not shown) and tested HCVpp infectivity. After dilu-
tion the virus-CD81 mixture was as infectious as untreated
virus, whereas minimal infectivity was detected in the vi-
rus-C1 mixture (Fig. 3C). Inhibition was observed when the
CD81 LEL was added after the dilution step (to a final
concentration of 5 g/ml). These data suggest that CD81
LEL does not irreversibly neutralize HCVpp or that it must
be present during the virus-cell incubation to inhibit infec-
tion. Finally, if the inhibitory effect(s) of recombinant CD81
LEL is dependent upon an interaction(s) with cell surface-
expressed CD81, one may expect the antiviral activity of
diverse CD81 LELs to differ according to the CD81 species
present on the target cell. The human hepatoma cell line
HepG2 does not express CD81 and can be rendered suscep-
tible to HCVpp infection by expression of human CD81 (4,
49). As shown in the following section, several nonhuman
CD81 sequences, including the AGM sequence, confer sus-
ceptibility to HCVpp upon HepG2 cells. Thus, we were able
to test the inhibitory activity of human and AGM CD81
LELs for HCVpp infection of HepG2 cells expressing hu-
man CD81 (Fig. 3D) or AGM CD81 (Fig. 3E). In both cases,
human CD81 LEL was a more potent inhibitor of viral
infectivity than AGM CD81 LEL, suggesting that inhibition
depends on the ability of the soluble CD81 to interact with
the virus and not cell surface-expressed tetraspanins.
Diverse CD81 proteins support HCVpp infection. Each of
the cloned CD81 sequences (human, AGM, chimpanzee,
tamarin, mouse, rat, or hamster) was expressed in HepG2
cells by using the pTRIP expression system and assessed for
its ability to support HCVpp infection. Although the human
and chimpanzee CD81 protein sequences are predicted to
be identical (Fig. 1), cells were transduced to express the
chimpanzee cDNA to rule out any effects that might arise
from differing nucleotide sequences. As a negative control,
cells were transduced to express CD9, a tetraspanin that
does not support HCVpp infection (49). Flow cytometric
analysis confirmed expression of each species of CD81 at the
cell surface (Fig. 4A). sE2 binding to the panel of full-length
CD81 proteins was assessed by flow cytometry (Fig. 4B). sE2
bound to HepG2 cells expressing human, tamarin, and chim-
panzee CD81 proteins, whereas negligible binding was ob-
served with HepG2 cells expressing CD9, AGM, mouse, rat,
or hamster CD81.
The susceptibility of each CD81-transduced cell line to HCVpp
infection was determined (Fig. 4C). As expected, expression of
human CD81 conferred susceptibility to infection by HCVpp
bearing E1E2 from H77 (genotype 1a), Con1 (genotype 1b), and
J6 (genotype 2a); incorporation of the H77 glycoproteins gave
rise to the most infectious HCVpp, whereas HCVpp-Con1 was of
intermediate infectivity and HCVpp-J6 the least infectious.
HCVpp bearing the strain H glycoproteins gave results similar to
those for the HCVpp-H77 (data not shown). Despite the lack of
interaction of sE2 with the AGM CD81-transduced cells, these
cells supported levels of infection similar to those for cells trans-
duced with the human, chimpanzee, and tamarin CD81 se-
quences. The pattern of infection was more complex for the
rodent CD81 sequences: mouse, hamster, and rat CD81 proteins
supported HCVpp-H77 infection; mouse and hamster, but not
rat, proteins supported HCVpp-Con1 infection; and mouse, ham-
ster, and rat proteins failed to support HCVpp-J6 infection (Fig.
4C). For each HCVpp, the rodent sequences supported lower
levels of infection than their primate homologues, likely reflecting
a reduced affinity between the HCV glycoproteins and the rodent
CD81.
Diverse CD81 proteins support HCVcc infection. It has re-
cently become possible to propagate infectious HCV particles
based on the JFH genotype 2a sequence in cell culture
(HCVcc) (25, 46, 50). We reported that chimeric J6/JFH virus
was able to infect HepG2 cells expressing human CD81, con-
firming that CD81 is critical for HCVcc infection (25). We
used this chimeric J6/JFH virus to determine whether our
panel of CD81 proteins could support HCVcc infection. At
72 h postinfection, the cells were immunostained for the HCV
nonstructural protein, NS5A (Fig. 5A). Multiple foci of NS5A-
positive cells were present in the HepG2 cells expressing hu-
man, chimpanzee, AGM, and tamarin CD81 proteins; fewer foci
were present in HepG2 cells expressing mouse or hamster CD81;
and a single positive cell was seen in the rat CD81-expressing
population (Fig. 5A). This suggests that rodent CD81 sequences
are less able to support HCV entry than the primate sequences,
consistent with the HCVpp infection data (Fig. 4C). Thus,
HCVpp infection reflects HCVcc entry, at least with regard to
CD81 sequence requirements.
To obtain a quantitative measurement of the efficiency with
which different CD81 sequences support HCVcc infection, we
used a reporter virus, J6/JFH(Rluc2Aubi), based on the J6/
JFH chimeric virus but expressing the Renilla luciferase gene.
The CD81-transduced HepG2 cells were infected with J6/
JFH(Rluc2Aubi) virus, and Renilla luciferase was measured
after 72 h (Fig. 5B). While luciferase signals were low com-
pared to those in HCVpp infections, HCVcc infection was
supported by human, AGM, chimpanzee, and tamarin CD81
proteins. Levels of infection were not clearly different from
background in HepG2 cells expressing rodent CD81 se-
quences, with mouse and hamster CD81 proteins marginally
above rat CD81 and the CD9 negative control.
Variant CD81 proteins support HCVpp infection. The ma-
jority of CD81 sequences tested conferred some degree of
susceptibility to infection by HCVpp or HCVcc (Fig. 4 and 5).
The least efficient CD81 sequence was rat, which conferred
modest levels of infection by HCVpp-H77/H, but not HCVpp-
Con1 or -J6 or HCVcc. Within the CD81 LEL, amino acids
178, 181, and 184 are unique to the rat sequence (Fig. 1).
Position 184 was previously reported to be important for sE2
binding (11). To evaluate whether amino acids at positions 178
and 181 are critical for HCV infection, we expressed CD81
molecules altered at these residues. The rat residues, either
singly or in combination, were introduced into the context of
the human CD81 (human CD81 G178S and G178S/I181S),
and the human residues were introduced into the context of
the rat sequence (rat CD81 S178G, S181I, and S178G/S181I).
To further our understanding of the importance of particular
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CD81 residues in HCV infection, amino acid changes previ-
ously reported to abrogate the sE2-CD81 LEL interaction
were introduced into the human CD81 (human CD81 I182F,
N184Y, and F186S and the three in combination, I182F/
N184Y/F186S) (11). The variant CD81 proteins were ex-
pressed in HepG2 cells, cell surface expression was confirmed
by flow cytometry (Fig. 6A), and cells were tested for infection
by pseudotype viruses. Surprisingly, when the individual changes,
or their combinations, were introduced into the human CD81
sequence, only moderate reductions in HCVpp-H infection
FIG. 4. CD81s from different species support HCVpp-glycoprotein mediated infection. (A) HepG2 cells were transduced with packaged lentiviruses
expressing different CD81 sequences or CD9 as a negative control, and stained with anti-CD81 MAbs (1.3.3.22, JS-81, or EAT-2), and analyzed for CD81
expression by flow cytometry. (B) CD81-transduced cell populations were incubated with HCV strain H sE2 protein, and binding was detected with
anti-E2 MAbs. FSC, forward scatter. (C) HepG2 cells transduced to express the different species of CD81 were infected with HCVpp generated without
a viral envelope (no env) or bearing H77, Con1, or J6 HCV E1E2 or VSV G glycoproteins. Cells were lysed and luciferase activity determined 3 days
after infection. All infections were performed in triplicate, and the mean luciferase activity is shown with standard deviation bars. Open bars, infection
with no Env-pp; diagonally hatched bars, infection with HCVpp-H77; horizontally hatched bars, infection with HCVpp-Con1; stippled bars, infection with
HCVpp-J6; black bars, infection with VSV-Gpp pseudotype virus. RLU, relative light units.
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were observed, and the luciferase signal for each was clearly
above that observed for rat CD81 (Fig. 6B). Conversely, re-
placement of the residues unique to the rat sequence with their
human counterparts (S178G, S181I, and S178G/S181I) did not
significantly modulate the levels of infection above that con-
ferred by wild-type rat CD81. One interpretation is that amino
acid changes outside the LEL contribute to the minimal re-
ceptor activity of rat CD81. To assess the role of regions outside
the LEL, chimeric human and rat CD81 proteins expressing the
heterologous species LEL (human-rat and rat-human) were gen-
erated, transduced into HepG2 cells, and tested for their ability to
support HCVpp-H77 and HCVcc infection. Both chimeric pro-
teins were expressed at the cell surface as determined by flow
cytometry (data not shown). HCVpp infected cells expressing the
FIG. 5. HCVcc infection is supported by multiple CD81 sequences. (A) HepG2 cells transduced to express CD81s from different species were
infected with J6/JFH HCVcc. At 72 h postinfection, cells were fixed and immunostained for NS5A. (B) HepG2 cells transduced to express CD81s
from different species were infected with HCVcc derived from the J6/JFH genotype 2a chimeric virus expressing the Renilla luciferase, J6/
JFH(Rluc2Aubi). Cells were lysed and luciferase activity determined 3 days after infection. All infections were performed in triplicate, and the
mean luciferase activity, after deduction of the mean background value from triplicate uninfected wells, is shown with standard deviation bars.
RLU, relative light units.
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chimeric CD81 containing the human but not rat LEL (Fig. 7A).
This pattern was confirmed using HCVcc encoding a luciferase
reporter, indicating that the LEL is the region of CD81 defining
HCV entry (Fig. 7B).
DISCUSSION
Initially identified as a binding partner for sE2, CD81 has
recently been shown to be essential for HCVcc infection (25,
FIG. 6. Mutated CD81 sequences confer susceptibility to HCVpp infection. (A) HepG2 cells were transduced with packaged lentiviruses
expressing wild-type or mutant CD81 sequences. Transduced cells were stained with anti-CD81 MAbs (1.3.3.22 or EAT-2) and analyzed for CD81
expression by flow cytometry. FSC, forward scatter. (B) HepG2 cells transduced to express mutant CD81 proteins were infected with HCVpp. Cells
were lysed and luciferase activity determined 3 days after infection. All infections were performed in triplicate, and mean luciferase activity is shown
with standard deviation bars. Depicted are results from a representative of two separate experiments. Open bars, infection with no-Env pseudotype
virus; hatched bars, infection with HCVpp-H; black bars, infection with MLVpp. RLU, relative light units.
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46, 50). The interaction between CD81 and the HCV glyco-
proteins is a potential target for therapeutic intervention. A
greater understanding of the structural requirements for CD81
to support infection may aid in the design of inhibitors of this
process. In this study, we used a series of CD81 sequences
derived from different species to investigate these require-
ments.
We studied CD81 sequences for their interaction with the
HCV glycoproteins in five independent assays: (i) sE2 binding
to GST-CD81 LEL proteins (Fig. 2B); (ii) GST-CD81 LEL
inhibition of HCVpp infection (Fig. 2C and 3); (iii) sE2 bind-
ing to cell surface-expressed, full-length CD81 proteins (Fig.
4B); and (iv) HCVpp (Fig. 4C, 6B, and 7A) and (v) HCVcc
(Fig. 5 and 7B) infection of cells expressing full-length CD81.
Consistent results were obtained in the first two assays using
recombinant CD81 LEL proteins; however, this was not pre-
dictive of the ability of full-length CD81 to support HCVpp
and HCVcc infection. sE2 interaction with cell surface-ex-
pressed CD81 also failed to predict virus-receptor interactions
leading to HCV entry. One explanation for these observations
is that recombinant sE2 and GST-CD81 LEL fail to mimic
their full-length counterparts. Truncated soluble forms of
strain H or HCV-1 genotype 1 E2 proteins have been reported
to bind CD81 with an affinity of 109 M (34), whereas E2
proteins cloned from other genotypes show minimal interac-
tion with CD81 (38, 40, 43). In contrast, it has been demon-
strated that HCVpp bearing diverse glycoproteins infect cells
in a CD81-dependent manner, despite the differing affinities of
their sE2s for CD81 (22, 29). Compared to E1E2 complexes,
sE2 has an increased rate of dissociation from CD81 LEL and
may be an inadequate model for multivalent viral particle
interactions with CD81 (6, 32). These data suggest that care
should be taken in interpreting the biological relevance of
studies using sE2 as a model for virus-CD81 interactions.
We previously reported that a GST-AGM CD81 LEL fusion
protein failed to interact with sE2 or to inhibit HCVpp infec-
tion (13, 15, 18). However, in this report we demonstrate a
low-affinity interaction between sE2 and GST-AGM CD81
LEL (Fig. 2B), as reported by others (1, 32). This difference
may reflect the extent of native folding of the recombinant
CD81 proteins used in the various studies. Characterization of
the recombinant CD81 proteins used in this study, with anti-
bodies whose recognition was dependent on disulfide bond
formation, indicated that disulfide bonds were formed in at
least a proportion of the human, mouse, and rat GST-CD81
LEL proteins (Fig. 2A). However, the GST-mouse CD81 LEL
failed to inhibit HCVpp infection (Fig. 2B), whereas the full-
length mouse CD81 was able to support infection by HCVpp
(Fig. 4C), suggesting that recombinant LEL proteins may not
accurately mimic native CD81 conformation. Several reports
have used recombinant tetraspanin LELs to study cell adhe-
sion and fusion, suggesting an interaction between soluble LEL
and target cell-expressed tetraspanins (16, 17, 44). Our exper-
iments demonstrate that incubation of human CD81 LEL with
Huh-7.5 cells does not affect HCV infectivity, that recombinant
LEL has to be present during the virus-cell incubation period
to block HCV entry, and that recombinant LEL inhibition of
HCVpp infectivity is independent of the CD81 sequence ex-
pressed on the target cell (Fig. 3). These data are consistent
with the observation that anti-CD81 antibodies neutralize cell
surface-bound HCVpp, suggesting that CD81 is not the pri-
mary attachment factor but is a critical cofactor (7).
Another factor to consider is that HCVpp and HCVcc in-
fection assays are likely to be more sensitive than the other
assays employed, where multivalent virus particles may interact
with cellular molecules in a cooperative manner, allowing
CD81 molecules with a low affinity for the viral glycoproteins
to function as a receptor. CD81 density is also likely to play a
role in HCV entry, such that overexpression of CD81 se-
quences at the surface of HepG2 cells may allow suboptimal
sequences to function as receptors. Cell surface receptor, and
coreceptor, densities have been reported to be important de-
terminants of HIV infection (8, 19, 21, 36). For example,
CCR3 and STRL33/Bonzo function as HIV type 1 coreceptors
only when expression exceeds a threshold level (39, 42). Con-
sistent with CD81 cell surface density being important for
HCVpp entry, silencing of expression in Huh-7.5 cells resulted
in a threefold reduction in surface CD81 but abrogated
HCVpp infection (49), suggesting that a threshold density is
required for infection. Importantly, while we cannot infer that
physiological levels of mouse, hamster, or AGM CD81 are
capable of supporting infection by HCV, it is clear that these
FIG. 7. Chimeric rat-human SEL-LEL CD81 proteins confer sus-
ceptibility to HCVpp and HCVcc infection. HepG2 cells were trans-
duced with packaged lentiviruses expressing parental or human-rat and
rat-human SEL-LEL swap proteins. HepG2 cells transduced to ex-
press human CD9 or the chimeric human CD81 proteins were infected
with (A) HCVpp-H77 (white bars) or VSV-Gpp (shaded bars) or
(B) HCVcc encoding a luciferase reporter, J6/JFH(Rluc2Aubi). All
infections were performed in triplicate, and mean luciferase activity is
shown with standard deviation bars.
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sequences can support HCV infection in the context of a hu-
man liver cell background.
The rodent CD81 sequences showed differences in their
ability to support HCVpp infection of particles bearing H77,
Con1, or J6 glycoproteins, suggesting differences in the affinity
of these CD81 proteins for diverse HCV glycoproteins (Fig.
4C). This conclusion is supported by the observation that hu-
man CD81 LEL neutralizes HCVpp-H77, -Con1, and -J6 in-
fection with various efficiencies (50% inhibitory concentrations
of 1.2 g/ml for H77, 5.6 g/ml for Con1, and 12.4 g/ml for
J6) (data not shown), consistent with a model where glycopro-
teins of different genotypes have different affinities for CD81
(29). Interestingly, the infectivity of HCVpp correlated with
their sensitivity to neutralization by human CD81 LEL.
All of the tested CD81 sequences were able to support some
level of HCV infection, though the rodent sequences were less
efficient than primate sequences. For both HCVpp-H77 and
J6/JFH HCVcc, the level of infection supported by the mouse
CD81 was approximately 10-fold less than that supported by
the human sequence (Fig. 4C). In contrast, Bertaux and Dragic
reported that transient expression of murine CD81 in HepG2
cells failed to allow HCVpp entry (5). This discrepancy may be
explained by differences in CD81 expression levels and the infec-
tivity of the inoculum used for challenge experiments. CD81 is not
the sole determinant of HCV host range, as transgenic mice
expressing human CD81 are not susceptible to HCV infection
(28). It is unclear whether the inefficiency of murine CD81 would
be sufficient to preclude propagation of HCV in mice. Nonethe-
less, the markedly reduced efficiency of rodent CD81 sequences
may be an important consideration in efforts to develop a small
animal model of HCV infection.
Given that rat CD81 was the least efficient of the tested
sequences, we aimed to define whether amino acid residues
178 and 181 within the LEL, which are unique to the rat
sequence, are critical for receptor function. Introduction of the
rat residues into human CD81 reduced, but did not abolish,
HCVpp infection (Fig. 6). Similarly, substitution of the human
residues into the rat CD81 had a minimal effect on HCVpp
infectivity. Chimeric human CD81 with rat LEL was unable to
support HCVpp infection, whereas the rat CD81 with human
LEL allowed HCVpp and HCVcc infection, demonstrating the
critical role of the LEL in HCV entry (Fig. 7). Hence, the low
efficiency of rat CD81 may be attributable not to one or two
single residues unique to the rat sequence but to several dif-
ferences from the human sequence that, in combination, result
in a low-affinity or suboptimal interaction(s) with the virus
particle.
Previous reports on the HCV-CD81 interaction studied
binding of sE2 to recombinant LEL or to full-length CD81
expressed at the cell surface. Those studies identified several
amino acid changes that inhibited sE2 binding: I182F, N184Y,
F186L, F186S, and D196E (11, 15). We previously demon-
strated that human CD81 bearing either F186L or D196E
could support HCVpp infection (49). Here, we analyzed a
number of additional residues important for sE2 binding, by
expressing human CD81 with I182F, N184Y, F186S, or all
three changes in combination. These changes, particularly in
combination, reduced but did not abrogate HCVpp infection
(Fig. 6), underscoring the robustness of the virus-CD81 inter-
action and the limited predictive power of sE2 binding with
regard to HCV glycoprotein-mediated cell entry.
Our findings highlight the limitation of biochemical assays
for studying HCV glycoprotein interactions with cellular re-
ceptors. Neither the binding of sE2 to recombinant or full-
length CD81 nor the ability of recombinant CD81 LEL to
inhibit HCVpp infection predicts the ability of CD81 se-
quences to support HCV entry. Thus, small molecules de-
signed to inhibit the interaction between recombinant proteins
may be inadequate to inhibit viral entry. Furthermore, our data
indicate a remarkable plasticity in the sequence of CD81 re-
quired to support infection. We were unable to identify single
amino acid positions in CD81 that are critical for HCVpp or
HCVcc entry. Finally, the observation that murine CD81 can
support HCV entry, albeit with reduced efficiency, may be
important information for the development of a small animal
model of HCV infection.
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